These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35316518)

  • 21. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.
    Song YS; Choi SH; Park CK; Yi KS; Lee WJ; Yun TJ; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Jahng GH; Chang KH
    Korean J Radiol; 2013; 14(4):662-72. PubMed ID: 23901325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab.
    Takano S; Kimu H; Tsuda K; Osuka S; Nakai K; Yamamoto T; Ishikawa E; Akutsu H; Matsuda M; Matsumura A
    Acta Neurochir Suppl; 2013; 118():185-9. PubMed ID: 23564129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.
    Lin X; Lee M; Buck O; Woo KM; Zhang Z; Hatzoglou V; Omuro A; Arevalo-Perez J; Thomas AA; Huse J; Peck K; Holodny AI; Young RJ
    AJNR Am J Neuroradiol; 2017 Mar; 38(3):485-491. PubMed ID: 27932505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors.
    Calli C; Kitis O; Yunten N; Yurtseven T; Islekel S; Akalin T
    Eur J Radiol; 2006 Jun; 58(3):394-403. PubMed ID: 16527438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation between glioblastomas and brain metastases and regarding their primary site of malignancy using dynamic susceptibility contrast MRI at 3T.
    Askaner K; Rydelius A; Engelholm S; Knutsson L; Lätt J; Abul-Kasim K; Sundgren PC
    J Neuroradiol; 2019 Nov; 46(6):367-372. PubMed ID: 30389510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy of apparent diffusion coefficients and enhancement ratios on magnetic resonance imaging in differentiating primary cerebral lymphomas from glioblastoma.
    Anwar SSM; Baig MZ; Laghari AA; Mubarak F; Shamim MS; Jilani UA; Khalid MU
    Neuroradiol J; 2019 Oct; 32(5):328-334. PubMed ID: 31188064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of the apparent diffusion coefficient for the evaluation of the white matter to differentiate between glioblastoma and brain metastases.
    Miquelini LA; Pérez Akly MS; Funes JA; Besada CH
    Radiologia; 2016; 58(3):207-13. PubMed ID: 26655126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiating brain metastasis from glioblastoma by time-dependent diffusion MRI.
    Kamimura K; Kamimura Y; Nakano T; Hasegawa T; Nakajo M; Yamada C; Akune K; Ejima F; Ayukawa T; Ito S; Nagano H; Takumi K; Nakajo M; Uchida H; Tabata K; Iwanaga T; Imai H; Feiweier T; Yoshiura T
    Cancer Imaging; 2023 Aug; 23(1):75. PubMed ID: 37553578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of apparent diffusion coefficient in differentiating between high-grade gliomas and brain metastases.
    Caravan I; Ciortea CA; Contis A; Lebovici A
    Acta Radiol; 2018 May; 59(5):599-605. PubMed ID: 28835111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Value of Minimum Apparent Diffusion Coefficient in Peritumoral Edema in the Differential Diagnosis between Primary Central Nervous System Lymphoma and Glioblastoma].
    Li MG; Chen ZY; Liu G; Xiao HF; Chen XJ; Lou X; Ma L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Apr; 40(2):146-150. PubMed ID: 29724302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multimodal MR Features of 8 Cases of Epithelioid Glioblastoma.
    Zhao JP; Cui CX; Wang JC; Su HW; Duan CF; Liu XJ
    Biomed Res Int; 2020; 2020():9586806. PubMed ID: 33123592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions.
    Sundgren PC; Fan X; Weybright P; Welsh RC; Carlos RC; Petrou M; McKeever PE; Chenevert TL
    Magn Reson Imaging; 2006 Nov; 24(9):1131-42. PubMed ID: 17071335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spectroscopic, diffusion and perfusion magnetic resonance imaging at 3.0 Tesla in the delineation of glioblastomas: preliminary results.
    Di Costanzo A; Trojsi F; Giannatempo GM; Vuolo L; Popolizio T; Catapano D; Bonavita S; d'Angelo VA; Tedeschi G; Scarabino T
    J Exp Clin Cancer Res; 2006 Sep; 25(3):383-90. PubMed ID: 17167979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DTI and PWI analysis of peri-enhancing tumoral brain tissue in patients treated for glioblastoma.
    Stecco A; Pisani C; Quarta R; Brambilla M; Masini L; Beldì D; Zizzari S; Fossaceca R; Krengli M; Carriero A
    J Neurooncol; 2011 Apr; 102(2):261-71. PubMed ID: 20658351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of combined use of DWI and percentage signal recovery-optimized protocol of DSC-MRI in differentiation of high-grade glioma, metastasis, and lymphoma.
    Cindil E; Sendur HN; Cerit MN; Dag N; Erdogan N; Celebi FE; Oner Y; Tali T
    Neuroradiology; 2021 Mar; 63(3):331-342. PubMed ID: 32821962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
    Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
    J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.
    Prah MA; Al-Gizawiy MM; Mueller WM; Cochran EJ; Hoffmann RG; Connelly JM; Schmainda KM
    J Neurooncol; 2018 Jan; 136(1):13-21. PubMed ID: 28900832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.
    Lee MD; Baird GL; Bell LC; Quarles CC; Boxerman JL
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1445-1450. PubMed ID: 31371360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.